FINWIRES · TerminalLIVE
FINWIRES

Citigroup Downgrades Evolent Health to Neutral From Buy, Adjusts Price Target to $6.75 From $5.50

By

Evolent Health (EVH) has an average rating of buy and mean price target of $5.96, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Craig Hallum Downgrades BioLife Solutions to Hold From Buy

Craig Hallum Downgrades BioLife Solutions to Hold From Buy

$BLFS
Research

Maxim Downgrades BioLife Solutions to Hold From Buy

Maxim Downgrades BioLife Solutions to Hold From Buy

$BLFS
Research

Deutsche Bank Upgrades UDR to Buy From Hold, Adjusts PT to $45 From $39

UDR (UDR) has an average rating of Hold and mean price target of $41.95, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $39.55, Change: $-0.02, Percent Change: -0.05%

$UDR